MacroGenics, Inc.
MGNXMacroGenics, Inc. is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for cancer and autoimmune diseases. The company leverages its proprietary protein engineering platform to create targeted treatments aimed at enhancing immune responses and improving patient outcomes.
Company News
MacroGenics, Inc. announced that its management team, led by President and CEO Eric Risser, will participate in four major investor conferences in March 2026, including TD Cowen, Leerink Partners, Citizens, and Barclays healthcare conferences. The company will conduct presentations, fireside chats, and one-on-one meetings with investors. Webcasts...
The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab, a bispecific antibody targeting PD-1 and CTLA-4 for gynecologic cancers. The hold follows safety events in four patients including Grade 4 thrombocytopenia, myocarditis, neutropenia with septic shock, and one death. No new patients will be enrolled un...
The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expa...
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.
